Does Pfizer offer financial support for patients with Inflectra?
Patient Support for INFLECTRA Pfizer offers financial support programs to assist patients with accessing INFLECTRA treatment, including: Pfizer enCompass™ Co-Pay Assistance Program for INFLECTRA – For patients with commercial insurance that covers INFLECTRA
How do I enroll in the Pfizer encompass™ co-pay assistance program?
To enroll in the Pfizer enCompass™ Co-Pay Assistance Program or to apply for the Pfizer Patient Assistance Program, access the forms below and fax them to Pfizer enCompass™ at 1-844-482-4482, or call Pfizer enCompass™ at 1-844-722-6672.
How to register for Pfizer’s Patient Assistance Program?
If you are a Patient already enrolled in Pfizer’s Patient Assistance Program, you can register by providing your email, name and Patient ID (used to validate your account). If you are a new Patient, you can create a new account and being your enrollment process. How to healthcare professionals register for Pfizer PAP Connect?
Who can investigate patients'insurance benefits and coverage details for Inflectra?
Pfizer enCompass™ Access Counselors can investigate patients' insurance benefits and coverage details for INFLECTRA *Administered by ConnectiveRx. See program full terms and conditions below. †For eligible patients.
See more
Does Pfizer have a patient assistance program?
Pfizer RxPathways® patients in need get access to their Pfizer medicines. Today, Pfizer RxPathways® connects eligible U.S. patients to a range of Pfizer assistance programs that provide insurance support, co-pay help, and medicines for free or at a savings.
Does INFLECTRA have copay assistance?
The Pfizer enCompass Co-Pay Assistance Program provides assistance for out-of-pocket drug costs associated with INFLECTRA due to co-pays, co-insurances, or deductibles, up to $20,000 per calendar year. You are responsible for the first $5 of each injection before the benefit may be used.
What is the name of Pfizer's patient assistance program for its infliximab biosimilar in the United States?
INFLECTRA® (infliximab-dyyb) for Healthcare professionals: Inflectra (infliximab – dyyb) for Injection U.S. Physician Prescribing Information.
What is Pfizer enCompass?
The Pfizer enCompass Co-Pay Assistance Program for RUXIENCE provides eligible, commercially insured patients assistance of up to $25,000 per calendar year for claims received by the program. Eligible enrolled patients may pay as little as $0 for each RUXIENCE treatment.
What is the cost of Inflectra?
SEB infliximab (Inflectra) is available as a 100 mg/vial solution for intravenous infusion at a manufacturer submitted price of $525.00 pervial.
Is Inflectra covered by insurance?
Inflectra (infliximab-dyyb), a biosimilar to Remicade (infliximab), is now covered by Medicare and Medicaid. Approved by the Food and Drug Administration in April 2016, Inflectra is the first biosimilar indicated for the treatment of rheumatic and inflammatory diseases to come to market in the United States.
How often do you get INFLECTRA infusions?
The recommended dosage of INFLECTRA is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of adult patients with moderately to severely active UC.
Is INFLECTRA as good as Remicade?
Remicade and Inflectra are biologic medications used to treat many autoimmune disorders. Inflectra is a biosimilar to Remicade, and they're both given by your healthcare provider as an infusion into your vein. There are no clinically meaningful safety or effectiveness differences between Remicade and Inflectra.
Does INFLECTRA cause weight gain?
Conclusion: Approximately 60% of Crohn's disease patients experience weight gain within the first six weeks of infliximab treatment. The weight increment correlates with improvements in inflammatory markers and disease activity.
What are the side effects of Inflectra?
Common side effects of Inflectra include: upper respiratory infections....Common side effects may include:stuffy nose, sinus pain;fever, chills, sore throat;cough, chest pain, shortness of breath;high or low blood pressure;headache, feeling light-headed;rash, itching; or.stomach pain.
Is Inflectra the same as Remicade?
Remicade (infliximab) and Inflectra (infliximab-dyyb) are biologic medications that treat many autoimmune disorders. Inflectra is highly similar — but not identical — to Remicade. Inflectra doesn't have clinically meaningful differences from Remicade. But it's usually cheaper for most people.
What are the side effects of Inflectra?
Common side effects of Inflectra include: upper respiratory infections....Common side effects may include:stuffy nose, sinus pain;fever, chills, sore throat;cough, chest pain, shortness of breath;high or low blood pressure;headache, feeling light-headed;rash, itching; or.stomach pain.
What is the medicine Entyvio?
ENTYVIO® (vedolizumab) | Ulcerative Colitis and Crohn's Disease. ENTYVIO is a prescription medicine used in adults for the treatment of: moderately to severely active ulcerative colitis. moderately to severely active Crohn's disease.
What is infliximab used for?
Descriptions. Infliximab injection is used to reduce the symptoms of moderate-to-severely active Crohn's disease and ulcerative colitis in adults and children who have been previously treated with other medicines but did not work well.
What is Pfizer Patient Assistance Program?
Pfizer Patient Assistance Program. Provides free Pfizer medicines to eligible patients through their doctor’s office or at home. To qualify, patients must: Have a valid prescription for the Pfizer medicine for which they are seeking assistance. Have no prescription coverage, or not enough coverage, to pay for their Pfizer medicine.
How to be evaluated for Pfizer?
To be evaluated for assistance, patients and their healthcare providers must submit a completed enrollment form. Patients must also provide proof of income, such as a W2 form, a paycheck stub, or prior year’s tax return. In some cases, patients prescribed certain Pfizer medicines may first be required to seek alternate forms of assistance before they can be considered for free medicine through the Pfizer Patient Assistance Program.
What is Pfizer Savings Program?
Pfizer Savings Program. Helps uninsured patients receive savings on more than 100 Pfizer medicines directly at their pharmacy, regardless of their income. Call 1-855-239-9869 to enroll. View available medicines.
How many Pfizer medicines are free?
The Pfizer Patient Assistance Program provides more than 60 Pfizer medicines for free to eligible patients through their doctor’s office, or in some cases, through home delivery.
What is the Pfizer phone number?
Patients can dial the toll-free phone number 1-844-989-PATH (7284) to consult with a Pfizer Medicine Access Counselor to find out if they meet the eligibility requirements.
How to contact Pfizer Rxpathways?
For more information about Pfizer RxPathways, please visit www.PfizerRxPathways.com. Patients can also call the toll-free phone number 1-844-989-PATH (7284) to consult with a Pfizer Medicine Access Counselor.
Can underinsured patients get free Pfizer?
Both uninsured and underinsured patients may be eligible for help. To qualify for free medicine through the Pfizer Patient Assistance Program, patients must*:
What is Inflectra used for?from accessdata.fda.gov
Inflectra is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.
How long does it take to take Inflectra?from drugs.com
The recommended dose of Inflectra is 5 mg/kg given as an intravenous induction regimen at 0, 2 and 6 weeks followed by a maintenance regimen of 5 mg/kg every 8 weeks thereafter for the treatment of chronic severe (i.e., extensive and/or disabling) plaque psoriasis.
How long does infliximab last?from accessdata.fda.gov
The safety and efficacy of infliximab in patients with juvenile rheumatoid arthritis (JRA) were evaluated in a multicenter, randomized, placebo-controlled, double-blind study for 14 weeks, followed by a double-blind, all-active treatment extension, for a maximum of 44 weeks. Patients with active JRA between the ages of 4 and 17 years who had been treated with MTX for at least 3 months were enrolled. Concurrent use of folic acid, oral corticosteroids (≤0.2 mg/kg/day of prednisone or equivalent), NSAIDs, and/or disease modifying antirheumatic drugs (DMARDs) was permitted.
What are the malignancies associated with TNF blockers?from accessdata.fda.gov
The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months (range 1 to 84 months) after the first dose of TNF blocker therapy. Most of the patients were receiving concomitant immunosuppressants. These cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports.
How long does it take for Infliximab to cause hypersensitivity?from drugs.com
Most hypersensitivity reactions (including anaphylaxis, urticaria, dyspnea, and/or hypotension), have occurred during or within 2 hours of infliximab product infusion.
How safe is Infliximab?from drugs.com
The safety and effectiveness of infliximab products for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients aged 6 years and older with moderately to severely active UC who have had an inadequate response to conventional therapy are supported by evidence from adequate and well-controlled studies of infliximab in adults. Additional safety and pharmacokinetic data were collected in an open-label pediatric UC trial in 60 pediatric patients aged 6 through 17 years (median age 14.5 years) with moderately to severely active UC (Mayo score of 6 to 12; Endoscopic subscore ≥2) and an inadequate response to conventional therapies. At baseline, the median Mayo score was 8, 53% of patients were receiving immunomodulator therapy (6-MP/AZA/MTX), and 62% of patients were receiving corticosteroids (median dose 0.5 mg/kg/day in prednisone equivalents). Discontinuation of immunomodulators and corticosteroid taper were permitted after Week 0.
What infections are treated with Infliximab?from accessdata.fda.gov
The infections most frequently reported were respiratory tract infections (including sinusitis, pharyngitis, and bronchitis) and urinary tract infections. Among patients treated with infliximab, serious infections included pneumonia, cellulitis, abscess, skin ulceration, sepsis, and bacterial infection. In clinical trials, 7 opportunistic infections were reported; 2 cases each of coccidioidomycosis (1 case was fatal) and histoplasmosis (1 case was fatal), and 1 case each of pneumocystosis, nocardiosis and cytomegalovirus. Tuberculosis was reported in 14 patients, 4 of whom died due to miliary tuberculosis. Other cases of tuberculosis, including disseminated tuberculosis, also have been reported postmarketing. Most of these cases of tuberculosis occurred within the first 2 months after initiation of therapy with infliximab and may reflect recrudescence of latent disease [see Warnings and Precautions (5.1)]. In the 1-year placebo-controlled studies RA I and RA II, 5.3% of patients receiving infliximab every 8 weeks with methotrexate (MTX) developed serious infections as compared to 3.4% of placebo patients receiving MTX. Of 924 patients receiving infliximab, 1.7% developed pneumonia and 0.4% developed tuberculosis, when compared to 0.3% and 0.0% in the placebo arm respectively. In a shorter (22-week) placebo-controlled study of 1082 RA patients randomized to receive placebo, 3 mg/kg or 10 mg/kg infusions with infliximab at 0, 2, and 6 weeks, followed by every 8 weeks with MTX, serious infections were more frequent in the 10 mg/kg infliximab group (5.3%) than the 3 mg/kg or placebo groups (1.7% in both). During the 54-week Crohn's II Study, 15% of patients with fistulizing Crohn's disease developed a new fistula-related abscess.
What is Pfizer Rxpathways?
Pfizer RxPathways connects eligible patients to a range of assistance programs that offer insurance support, co-pay help, and medicines for free or at a savings. Patients and physicians can contact RxPathways at (866) 706-2400 or visit the website for more information on these programs www.pfizerrxpathways.com.
How much infliximab-dyyb is in a vial?
For injection: 100 mg of infliximab-dyyb as a white lyophilized powder in a single-dose vial for reconstitution and dilution.
How many vials are infliximab-dyyb?
INFLECTRA (infliximab-dyyb) for injection is supplied as one single-dose vial...
How to contact FDA Medwatch?
Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at https://vaers.hhs.gov or call (800) 822-7967.
How to report a drug to the FDA?
You may also report to the U.S. Food and Drug Administration (FDA) by visiting www.fda.gov/medwatch or by calling the U.S. FDA at (800)-332-1088.
What is the molecular weight of Infliximab Dyyb?
It has a molecular weight of approximately 149.1...
What is the phone number for InflECTRA?
Have been prescribed INFLECTRA® (infl iximab-dyyb) for Injection (For help with any other Pfi zer medicines, or to learn about Pfi zer’s other assistance programs, please call 844-989-PATH (7284) to speak with a Medicine Access Counselor (M-F, 8 AM - 6 PM ET)
What is Pfizer's information?
The information you provide will be used by Pfizer to improve and tailor our products and services to better serve you. The information will 3 also be used by the Pfizer Patient Assistance FoundationTM and parties acting on their behalf to administer and improve Pfizer’s assistance programs, to communicate with you about your experience with Pfizer’s assistance programs, and/or to send you materials and other helpful information and updates relating to Pfizer programs.
Is Pfizer a joint company?
is a joint program of Pfizer Inc. and the Pfizer Patient Assistance FoundationTM. The Pfizer Patient Assistance Foundation is a separate legal entity from Pfizer Inc. with distinct legal restrictions.
